6505--Levetiracetam Tablets
ID: 36E79726R0001Type: Solicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/workspace/contract/opp/424dd3bd99834ef08ccbf9cc7899aa26/view
Timeline
    Description

    The Department of Veterans Affairs is seeking offers for the procurement of Levetiracetam Tablets, a critical pharmaceutical product used in the treatment of epilepsy. This solicitation, identified as 36E79726R0001, aims to establish a supply source for these tablets, covering a base year and four one-year option periods, with an aggregate award for seven line items of various strengths and bottle sizes. The awarded contractor will be responsible for distribution through the VA and DoD Pharmaceutical Prime Vendor Programs and must comply with stringent regulatory requirements, including FDA product registration and adherence to packaging standards. The deadline for submitting offers has been extended to December 3, 2026, at 2:30 PM Central Time, and interested parties should contact Contract Specialist Youlanda Duggar at youlanda.duggar@va.gov for further information.

    Point(s) of Contact
    Youlanda DuggarContract Specialist
    youlanda.duggar@va.gov
    Files
    Title
    Posted
    36E79726R0001 0001.docx
    This document is an amendment (0001) to solicitation 36E79726R0001, issued by the Department of Veterans Affairs, OPAL / National Acquisition Center. The primary purpose of this amendment is to extend the due date and time for receiving offers for Levetiracetam Tablets. The new deadline for offer submissions has been extended from November 26, 2025, to December 3, 2025, at 2:30 PM Central Time. All other terms and conditions of the original solicitation remain unchanged. Offerors are required to acknowledge receipt of this amendment by including a completed and signed copy with their proposal. The amendment emphasizes that failure to acknowledge receipt prior to the specified deadline may result in the rejection of an offer.
    36E79726R0001_1.docx
    The Department of Veterans Affairs (VA) National Acquisition Center intends to issue an unrestricted Request for Proposal (RFP) 36E79726R0001 for Levetiracetam Tablets. This procurement aims to secure an uninterrupted supply for the VA (including CMOPs and SVH), Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). One contract will be awarded for a one-year base period with four one-year option periods. Offerors must provide drugs with unique NDC numbers and specific packaging requirements, including safety-caps and bottle dimensions. The solicitation, with NAICS code 325412, will be issued electronically around November 10, 2025, with a tentative closing date of November 24, 2025. All updates will be available on sam.gov. Estimated annual usages for various Levetiracetam tablet strengths are detailed. The point of contact is Youlanda Duggar.
    36E79726R0001.docx
    This government solicitation, 36E79726R0001, is issued by the Department of Veterans Affairs (VA) to establish a supply source for Levetiracetam tablets. The contract will cover a base year and four one-year option periods, with one award made in aggregate for seven line items of various strengths and bottle sizes. Offerors must submit prices for all line items across all years, including a 0.5% Cost Recovery Fee. The contract involves distribution through VA and DoD Pharmaceutical Prime Vendor (PPV) Programs, requiring the awarded contractor to establish business-to-business agreements with PPVs. Key requirements include product registration with FDA, First Databank, Medispan, and Cerner Multum, adherence to packaging and barcoding standards (including DSCSA), and possession of necessary FDA drug applications. The solicitation also details procedures for backorders, recalls, and compliance with manufacturing facility cGMP status. Sales reports and Cost Recovery Fee payments are due quarterly. Covered drugs must meet 38 U.S.C. § 8126 requirements and offerors must have existing Master Agreements and Pharmaceutical Pricing Agreements with VA FSS.
    Lifecycle
    Title
    Type
    6505--Levetiracetam Tablets
    Currently viewing
    Solicitation
    6505--Levetiracetam Tablets
    Presolicitation
    Similar Opportunities
    760-25-1-050-0154 -Leavenworth CMOP THYROID TABLETS -(VA-25-00022614)
    Buyer not available
    The Department of Veterans Affairs is soliciting proposals for the procurement of Armour Thyroid tablets for the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) under solicitation number 36C77025Q0079. This Request for Quotation (RFQ) emphasizes the need for specific brand-name pharmaceuticals, with a focus on compliance with federal regulations, including the Drug Supply Chain Security Act and the Buy American Act. The procurement process aims to ensure a reliable supply of essential medications for veterans, with a firm-fixed-price contract expected to be awarded based on fair market evaluations. Interested vendors must submit their quotes by December 27, 2024, at 4:00 PM CST, and can direct inquiries to Jennifer L. Knight at jennifer.knight@va.gov or by phone at 913-684-0162.
    6505--Zonisamide Capsules
    Buyer not available
    The Department of Veterans Affairs (VA) intends to issue a Request for Proposal (RFP) for the unrestricted procurement of Zonisamide Capsules, which will serve various federal entities including the Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). The contract will be awarded to a single offeror capable of providing an uninterrupted supply of the specified medications, with a contract period of one year and four optional one-year extensions. The procurement is critical for ensuring the availability of these pharmaceutical products, which are essential for patient care within the VA and other federal health facilities. Interested parties should monitor SAM.gov for the solicitation, expected to be issued around December 15, 2025, with a closing date of December 30, 2025, and may direct inquiries to Chris Carthron at Christopher.Carthron@va.gov.
    VISN 21 Lenalidomide Capsules Multiple Strengths (Generic)
    Buyer not available
    The Department of Veterans Affairs (VA) is conducting a Sources Sought notice to identify vendors capable of supplying Lenalidomide Capsules in multiple strengths, specifically for VISN 21, which includes locations in California, Hawaii, Nevada, and Manila, Philippines. The contractor must be a Certified Lenalidomide REMS Pharmacy, licensed in the applicable states, and comply with all relevant federal, state, and VA regulations, including USP <800> for hazardous drugs. This procurement is critical as Lenalidomide is an oral anti-cancer medication, and the contract will span five one-year ordering periods from March 1, 2026, to February 28, 2031, requiring timely and compliant delivery of FDA-approved products. Interested vendors should submit their capability statements and relevant information to David J. Alvarez at david.alvarez4@va.gov by 10:00 AM Pacific Time on December 10, 2025.
    6505--Biologics by McKesson Specialty Pharmacy (Lenalidomide) (VA-26-00016920)
    Buyer not available
    The Department of Veterans Affairs is seeking qualified suppliers to provide Lenalidomide, a pharmaceutical product, for the Oscar G. Johnson VA Medical Center located in Iron Mountain, MI. This procurement will be conducted through a Brand Name or Equal Request for Quotation (RFQ) under firm-fixed price terms, following FAR Part 13 Simplified Acquisition Procedures. Lenalidomide is crucial for treating certain conditions, making this procurement significant for patient care within the VA system. Interested offerors must submit an itemized quote along with sufficient technical documentation via email to arneil.genus@va.gov by 3 p.m. Central on December 1, 2025, as telephone inquiries will not be accepted.
    Dimethyl Fumarate DR Presolicitation
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Metaxalone Tablets
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the supply of Metaxalone 800 MG tablets, available in both 100-count and 500-count bottles. This procurement aims to establish a requirements contract with estimated annual quantities for a base year and four option years, emphasizing the need for compliance with various federal regulations and the submission of a subcontracting plan for large businesses. Metaxalone is a critical medication used for muscle relaxation, highlighting the importance of reliable supply for military personnel. Interested vendors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) between November 7 and December 7, 2025, at 3:00 PM EST, and can reach out to Jeremy Brown or Jason Wray for further inquiries.
    Sertraline Tablets
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting offers for the procurement of Sertraline Tablets in 25MG, 50MG, and 100MG dosages, with various bottle counts required over a base year and four option years. This solicitation, identified as SPE2D2-26-R-0002, emphasizes the importance of these pharmaceuticals in supporting military personnel's health and well-being. Interested contractors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by December 10, 2025, at 3:00 PM EST, and adhere to specific contractual obligations, including a subcontracting plan and compliance with various FAR and DFARS clauses. For further inquiries, potential bidders can contact Christopher Newman at christopher.newman@dla.mil or Jason Wray at jason.wray@dla.mil.
    Rabeprazole Sodium Delayed Release Tablets
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    Q517--36C249-26-AP-0130 - VISN - Annual Wall-to-Wall Pharmacy Inventory
    Buyer not available
    The Department of Veterans Affairs, through the Network Contracting Office 9, is seeking proposals for Annual Wall-to-Wall Pharmacy Inventory services across various VA Medical Centers within VISN 09. The procurement aims to secure contractor support for the physical counting of both controlled and non-controlled pharmacy drugs, ensuring reconciliation with automated systems and compliance with VA, DEA, and FDA regulations. This service is critical for maintaining accurate inventory records and ensuring the proper management of pharmaceutical supplies within the VA healthcare system. Interested parties, particularly Service-Disabled Veteran-Owned Small Business Concerns (SDVOSBC), should note that the solicitation is anticipated to be issued on December 8, 2025, with responses due by December 15, 2025, and the contract award expected on December 17, 2025. For further inquiries, contact Mario Russell at mario.russell@va.gov.
    6505--Positron Emission Tomography (PET) Radiopharmaceuticals for the Albany VA Medical Center
    Buyer not available
    The Department of Veterans Affairs is seeking qualified contractors to provide Positron Emission Tomography (PET) Radiopharmaceuticals for the Albany VA Medical Center. This procurement is structured as a five-year, firm fixed-price, Indefinite Delivery, Indefinite Requirements (IDIQ) contract, which includes a 12-month base period and four 12-month option periods. The required radiopharmaceuticals include F18 FDG Fluorodeoxyglucose, F18 NaF Sodium Fluoride, Pylarify (piflufolastat F18), Neuroceq (florbetaben F18), and Flyrcado (flurpiridaz F18), all essential for patient care in the Nuclear Medicine Department. Interested contractors must be licensed by the United States Nuclear Regulatory Commission (NRC) and the Food and Drug Administration (FDA) to manufacture and distribute these products in New York State, with responses due by 12:00 PM Eastern Standard Time on December 8, 2025. For further inquiries, contractors can contact Jonathan Kilgore, the Contracting Officer, at jonathan.kilgore@va.gov or by phone at 973-676-1000.